BridgeBio announced that the Palo Alto, Calif.-based biopharmaceutical company signed an exclusive deal with Bristol Myers Squibb to develop and commercialize a potential treatment for cancer.
Generic drugmakers to sell Pfizer’s Paxlovid for $25 or less in low-income countriesClinton Health Access Initiative (CHAI), COVID-19 Therapeutic, COVID-19 Therapeutics, COVID-19 Therapies, Drug Pricing, Generic Substitution, Generics, Low-Income Countries, Medicines Patent Pool, Middle-Income Countries, Pfizer, Therapeutics, United Nations
Several generic drugmakers that will produce versions of Pfizer’s COVID-19 antiviral treatment Paxlovid agreed to sell the medicine in low-income and middle-income countries for $25 a course or less, the Clinton Health Access Initiative (CHAI) said on May 12.
Moderna Inc. has made all necessary submissions required by the U.S. Food and Drug Administration for emergency use authorization of the company’s COVID-19 vaccine in adolescents and children.
Arkansas sues drugmakers, pharmacy benefit managers over insulin costsArkansas, Blockbusters, Cigna, CVS Health, Eli Lilly, Express Scripts Holding, Insulin, Lawsuits, Novo Nordisk, OptumRx, Pharmacy Benefit Managers, Prescription Drug Costs, Retail Pharmacies, Sanofi, Therapeutics, UnitedHealth Group
The Arkansas attorney general on May 11 accused drugmakers and pharmacy benefit managers of colluding to drive up the price of insulin drugs, the latest in a series of lawsuits to take aim at skyrocketing costs for the life-sustaining medicine.
Just as Emergent BioSolutions looked to be making some headway in course corrections following a production mishap that ruined millions of doses of Johnson & Johnson’s COVID-19 vaccine, new information indicates the Maryland-based company sought to hide the deficiencies from federal regulators, all while touting its manufacturing capabilities, according to a BioSpace article.
Pfizer Inc.’s $11.6 billion deal for migraine specialist Biohaven Pharmaceutical has kindled expectations on Wall Street that the transaction may usher in more buyouts as cash-flush drugmakers look to snap up beaten-down smaller biotechs.
The U.S. Food and Drug Administration granted approval for the commercialization of Eli Lilly and Company and Incyte Corporation’s Olumiant (baricitinib), setting a precedent for COVID-19 treatments.
The Institute for Clinical and Economic Review recommended two out of three outpatient treatments for COVID-19 in the market, singling out molnupiravir as having inadequate evidence to support claims that it is better than symptomatic care.
AstraZeneca and Sanofi’s Phase III and Phase IIb clinical trials investigating the efficacy of nirsevimab, measured through the development of secondary infections, are impressing the pharma community with positive prespecified pooled analysis results. The data shows 79.5 percent efficacy in the prevention of lower respiratory tract infections, caused by infection of the respiratory syncytial virus (RSV).
Moderna Inc. Chief Financial Officer Jorge Gomez departed a day after taking charge, the vaccine maker said on May 11, following his former employer disclosing an internal probe related to financial reporting.